Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has reported revenues of $17.56bn for the fourth quarter ended 31 December 2010, an increase of 6%, compared to $16.54bn for the same period in 2009.
Subscribe to our email newsletter
For the fourth quarter of 2010, the net income attributable to Pfizer was $2.89bn, compared to $767m for the same period in 2009.
For the full year ended 31 December 2010, the company posted revenues of $67.81bn, compared to $50.01bn for the same period in 2009.
Net income attributable to Pfizer was $8.26bn for the full year of 2010, compared to $8.64bn for the same period in 2009.
For fourth-quarter 2010, revenues from Biopharmaceutical were $15.1bn, an increase of 3% compared with $14.6bn in the year-ago quarter.
Pfizer president and CEO Ian Read said he is pleased with the solid financial performance again this quarter and this year despite continued challenging market conditions.
"After evaluating our operating plans and capital allocation opportunities, we have adjusted our 2012 revenue target to exclude the projected contribution from future business development transactions and have reallocated funding to support an attractive, near-term opportunity to significantly increase our share repurchase activity," Read said.